It is conceivable that perceptions may vary considerably among women whose risks are significant for certain cancers, such as endometrial and ovarian cancers (e.g. MSH2), compared to those with lower risk (e.g. PMS2) [1]. This evidence concerns the gene MSH2 and ovarian carcinoma.